ZyVersa Therapeutics, Inc. ZVSA
Set alert
0.00 USD 0.00 0.00%
At close · Oct 29
0.29 +0.29 +28,800.00%
After hours · Oct 29, 4:00 PM ET
0.0415 Day range 0.05
0.001 52-week range 0.27
- YTD
- -99.25%
- 1 year
- -99.29%
- Open
- 0.0455
- Prev close
- 0.001
- Mkt cap
- 8.10K
- Vol
- 77.96K
- Avg vol
- 10.27K
- EPS
- -2.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0415
- High
- 0.05
- Forward P/E
- -0.24
- Beta
- 0.64
- Short ratio
- 0.19
- Inst. own
- 4.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.52
- 200-d avg
- 3.80
- 1y target
- 20.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -2.43; estimate -5.8; surprise 58.1%
Signals (108)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 2, 2026 | 4 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 5, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 16, 2026 | 6 months ago |
| SMA: Bearish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 19, 2026 | 7 months ago |
| SMA: Bullish | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 7 months ago |
| SMA: Bullish | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 4, 2026 | 8 months ago |
| SMA: Bearish | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 27, 2026 | 9 months ago |
| RSI: Overbought | Jan 9, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 26, 2025 | 10 months ago |
| SMA: Bearish | Dec 18, 2025 | 10 months ago |
| SMA: Bullish | Dec 17, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 17, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 11, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Nov 18, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 7, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 28, 2025 | 1 year ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 15, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 14, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| SMA: Bearish | Sep 26, 2025 | 1 year ago |
| SMA: Bullish | Sep 24, 2025 | 1 year ago |
| RSI: Oversold | Aug 28, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 6, 2025 | 1 year ago |
| RSI: Oversold | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | Jun 10, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| SMA: Bearish | Jun 3, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 29, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| SMA: Bullish | Apr 8, 2025 | 1 year ago |
| RSI: Overbought | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 27, 2025 | 1 year ago |
| RSI: Oversold | Mar 12, 2025 | 1 year ago |
| RSI: Oversold | Mar 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 30, 2025 | 1 year ago |
Key statistics
- Market cap
- 2.74M
- Enterprise value
- 1.04M
- Trailing P/E
- 0.00
- Forward P/E
- -0.24
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.04
- EPS (TTM)
- 491.97
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.54M
- Total cash
- 119.49K
- Total debt
- 0
- Return on equity
- -152.23%
- Shares outstanding
- 2.34M
- Short % of float
- 4.24%
- 50-day average
- 1.52
- 200-day average
- 3.80
Analyst view
Consensus: none
Price target (mean) 20.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -2.73.
Financials — quick view
ZVSA Revenue — quarterly 0
ZVSA Net income — quarterly -2.26M
ZVSA EPS — quarterly -0.73
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -5.80 | -2.43 | +3.37 | +58.10% |
| Aug 9, 2024 | Jun 1, 2024 | -5.20 | -3.31 | +1.89 | +36.35% |
| Aug 9, 2024 | Jun 1, 2024 | -5.20 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -3.70 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -3.70 | -4.53 | -0.83 | -22.43% |
| Mar 26, 2024 | Dec 1, 2023 | -2.14 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zyversa.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ZVSA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.11% | 2,566 | 3.00K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 433 | 506 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 1 | Sep 29, 2024 |
| Royal Bank of Canada | 0.00% | 52 | 60 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 8 | 9 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 1 | 1 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.21% | 4,950 | 5.79K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 1,614 | 1.89K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 50 | 58 | Sep 29, 2024 |